FDA Finds Increased Risk of Blood Clots in Lungs in RA Patients Taking Xeljanz at Higher Doses in Clinical Trials
This article represents the opinions, thoughts, and experiences of the author; none of this content has been paid for by any advertiser. The RheumatoidArthritis.net team does not recommend or endorse any products or treatments discussed herein. Learn more about how we maintain editorial integrity here.
- Xeljanz, Xeljanz XR (tofacitinib): Safety Communication - Safety Trial Finds Increased Risk of Blood Clots in the Lungs and Death with Higher Dose in Rheumatoid Arthritis Patients. Fda.gov. https://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm632016.htm. Published 2019. Accessed March 2, 2019.
- New FDA Drug Safety Communication on tofacitinib - Drug Information Update. App.info.fda.gov. http://app.info.fda.gov/e/es?s=2027422842&e=188607&elqTrackId=78D8A052C380BCBFF284D754BEBE9730&elq=5a972ecd64ee4024b14ae7fd674966c6&elqaid=6884&elqat=1. Published 2019. Accessed March 2, 2019.
- Pulmonary embolism: Take measures to lower your risk - Symptoms and causes. Mayo Clinic. https://www.mayoclinic.org/diseases-conditions/pulmonary-embolism/symptoms-causes/syc-20354647. Published 2019. Accessed March 2, 2019.